Bridge GLP compliant drug development in the US & China
Press Releases
< Return back to Press Releases
Bridge Laboratories Receives $18 million Financial BackingDecember 15 - San Francisco, CA Contact: Gil Bashe Makovsky and Company New York 212-508-9600 December 15, 2006, San Francisco, CA – Bridge Global Pharmaceuticals, Inc. a global leader in preclinical drug evaluation studies, today announced its acquisition of US-based Gene Logic Labs (GLL). Bridge will retain the services of all GLL employees, and the acquired unit's name will become Bridge Global Pharmaceutical Services, Inc. (a subsidiary of Bridge Laboratories) on December 18, 2006. Simultaneously Bridge and Gene Logic Inc. entered into a preferred services agreement for preclinical drug development. Acquisition of the Gene Logic Labs US facility enables Bridge to offer a complete IND suite of toxicology and pharmacology services on a global scale. Combining the experience, technical staff and resources of US operations with existing scientific staff in the new, purpose built facility in Beijing, China, Bridge will provide the pharma industry with the high quality data required for world wide regulatory submissions with very significant cost savings. About Pharmaron Founded in 2003, Pharmaron is a leading pharmaceutical and biotechnology drug R&D CRO, with operations in China and the United States. Clients include pharmaceutical, biotechnology, academic and government organizations. As a research-driven and customer-focused company, Pharmaron provides a broad, integrated portfolio of laboratory and manufacturing services from drug discovery to IND submission. These services are designed to help its global partners improve the success of research and shorten the time of development cost effectively in discovering and developing drugs. For more information about Pharmaron, please visit http://www.pharmaron.com. |